Human Genome Sciences News

Main Category: Cancer / Oncology Also Included In: Clinical Trials / Drug Trials Article Date: 24 Nov 2009 Human Genome Sciences, Inc.

After an agonizing wait of more than 40 years, science may come up with a treatment for lupus.

Nov 16, 2009 - Human Genome Sciences, Inc. today announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration relating to the Company's Biologics License Application requesting the approval of raxibacumab for use in the treatment of inhalational anthrax.

Northwest Pipe Co. shares tumbled Thursday after the maker of welded steel pipes said it has delayed the release of its third-quarter financial results, but that it expects to post a $1 million loss.

There's no denying that Mad Money host Jim Cramer is entertaining, popular, and passionate .

Emerging Stock Report, a leading provider of sector specific independent investment research, today initiated coverage on Human Genome Sciences .

Human Genome reports positive data on lupus drug >> Posted By altnrg 7 hours, 39 minutes ago in Health & Fitness Human Genome Sciences and GlaxoSmithKline said Monday their experimental lupus treatment passed another key goal on its path to potentially becoming the first new drug for the disease in decades.

Systemic lupus is the most common form of the autoimmune disease, lupus , which afflicts about five million people worldwide and causes a slew of symptoms including fever, pain and swelling.

Human Genome Sciences and GlaxoSmithKline said Monday their experimental lupus treatment passed another key goal on its path to potentially becoming the first new drug for the disease in decades.

Nov. 2 -- Thomas Watkins, chief executive officer of Human Genome Sciences Inc., talks with Bloomberg's Carol Massar and Matt Miller about the outlook for U.S. regulators' approval of the company's experimental lupus drug Benlysta.

November 5, 2009 Human Genome Sciences, Inc. and GlaxoSmithKline PLC recently announced that BENLYSTA met the primary endpoint in BLISS-76, the second of two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus .

Here's what Jim Cramer had to say about some of the stocks that callers offered up during the "Mad Money Lightning Round" Wednesday evening.

Human Genome Sciences and GlaxoSmithKline announced positive results from BLISS-76, the second of two large-scale phase III clinical trials of BENLYSTA for treating systemic lupus.

Rockville-based Human Genome Sciences, a listed biotechnology company in U.S., announced Monday that its experimental lupus treatment passed another key goal on its path to potentially becoming the first new drug for the disease in decades.

ROCKVILLE, Maryland, e LONDRES-- --A Human Genome Sciences, Inc. e a GlaxoSmithKline PLC anunciaram hoje que o BENLYSTA atingiu o endpoint prim&#22... CAMBRIDGE, Mass.-- --InterSystems Corporation today announced that NexJen Systems, Inc.

This story was corrected on Nov. 3, 2009. An explanation of the correction is at the end of the story.

Lean inventories, contained costs and improving sales should propel profit growth at Nordstrom Inc., said Deutsche Bank analyst Bill Dreher on Nov.

Usually, confirmatory phase 3 trials don't cause 40% gains in a stock. Especially after the first one resulted in a crazy 500%-plus gain.

Stock-PR.com, a division of Crown Equity Holdings Inc. tracks stocks daily and is pleased to offer its hot stock alerts.

Here are some of the latest health and medical news developments, compiled by editors of HealthDay : An experimental lupus drug called Benlysta was effective in its second large clinical trial, and drug makers Human Genome Sciences and GlaxoSmithKline will seek European and U.S. approval of the drug in the first half of 2010.